Invasive Meningococcal Disease Cases Rising in the U.S. According to Data
New data from 2023 and 2024 has revealed a concerning trend of increasing cases of invasive meningococcal disease in the United States. This rare bacterial infection has the potential to invade the nervous system or bloodstream, posing a serious threat to vulnerable demographics such as infants, individuals with weakened immune systems, and those taking certain medications.
In 2023, the U.S. reported a staggering 422 cases of meningococcal disease – the highest number since 2014. As of 2024, 143 cases have already been reported, indicating a continuation of this troubling trend. Up to 10-15% of patients affected by meningococcal disease can ultimately die from the infection.
To address this alarming increase, the Centers for Disease Control and Prevention (CDC) is urging doctors to maintain a heightened suspicion for meningococcal disease and to check their patients’ vaccine status. The CDC recommends the MenACWY vaccine for children at age 11 or 12, with a booster dose recommended at age 16.
Recent infections have been primarily tied to serogroup Y of the N. meningitidis bacteria, with strain ST-1466 identified as responsible for the majority of serogroup Y infections in 2023. While meningococcal disease most commonly presents as meningitis, cases of bloodstream infections and septic arthritis have also been reported.
Symptoms of meningococcal disease can include a purple rash, fever, and rapid breathing. Immediate antibiotic treatment is critical for those diagnosed with the disease. Fortunately, all samples of the ST-1466 strain have responded to the recommended antibiotics, although some strains have been found to be resistant to certain medications.
As cases of invasive meningococcal disease continue to rise in the U.S., it is crucial for healthcare providers and the public to remain vigilant and informed about the risks associated with this potentially deadly infection.
